glp 1 agonists and sglt2 inhibitors combination Combining glucagon-like peptide-1 receptor (GLP-1RAs) sodium-glucose cotransporter-2 (SGLT2is) in patients with type 2 diabetes mellitus (T2DM) | Cardiovascular Diabetology SGLT2 Inhibitors and GLP-1 Receptor
Description
Journal of Biochemical and Molecular Toxicology
Common side effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhea
[22] Vilsbll T, et al
GLP-1 receptor agonists work by mimicking the incretin hormone glucagon-like peptide-1, which enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety
While the new messaging seems to be that obesity is a genetic disease that we can manage with drugs, theres undoubtedly more to why conditions stemming from metabolic syndrome werent so common half a century ago
Quite possibly both
